Real-World evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex

Highly purified cannabidiol (CBD) with a known and constant composition has proven to be an effective and safe therapeutic alternative for the treatment of drug resistant epilepsy [1,2]. The results of several randomized controlled clinical trials have allowed it to be approved by various drug regulatory entities as adjuvant therapy in patients older than 2 years with drug resistant epilepsy associated with Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex [3 –7]. However, the mechanism of action of CBD in epilepsy, although not fully described, is multifactorial and is not exclusively related to the pathophysiology of these epileptic syndromes [8].
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Source Type: research